Business
Regen BioPharma Issues End of Fiscal Year Shareholder Letter
Regen BioPharma Issues End of Fiscal Year Shareholder Letter.
About this update from Regen Biopharma, Inc.
[{"type":"text","content":"\n\n\n\nRegen BioPharma Issues End of Fiscal Year Shareholder Letter\n\n\n\n\n\nRegen BioPharma Issues End of Fiscal Year Shareholder Letter\nPR Newswire\nSAN DIEGO, September 19, 2017\n\n\n\nSAN DIEGO, September 19, 2017 /PRNewswire/ --\n\nRegen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP) President Dr. Harry Lander issued the following  fiscal year end shareholder letter:\n\nAs the end of Regen's fiscal year 2017 approaches on September 30th, I would like to summarize our progress during the past twelve months and look to the future.\n\nThe Marketplace: \n\nOur decision to focus on small molecules to activate and inhibit our primary target of interest, NR2F6, seems prescient. The M&A market indicates that the autoimmunity and immuno-oncology fields are even hotter at the end of the year than they were at the beginning.  Although there have been many transactions over the past twelve months, two very recent deals further support this assertion: the $2.3 billion acquisition of IFM Therapeutics, Inc. by Bristol Myers Squibb (which I commented on previously (http://www.prnewswire.com/news-releases/regen-biopharma-inc-addresses-potential-impact-of-recent-bristol-myers-squibb-23-billion-acquisition-of-ifm-therapeutics-639392183.html), and the $11.9 billion acquisition of Kite Pharmaceuticals by Gilead (http://www.gilead.com/news/press-releases/2017/8/gilead-sciences-to-acquire-kite-pharma-for-119-billion).  \n\nA Look Back at our Success: \n\nThe scientific program focusing on identifying and optimizing small molecule compounds that activate or inhibit NR2F6 and directly inhibit or activate the immune system, respectively, is proceeding well. To our great excitement, we believe we are only three or four months away from having an optimized activator in hand, which we can then test in several animal models of autoimmunity.  Similarly, we also expect to have an optimized inhibitor a few months afterward (in calendar Q1 of 2018), which we can then test it in several animal models of cancer.  \n\nPlans for the Immediate Future: \n\nWe continue to have discussions with multiple big pharma companies. To create the most value for our shareholders, we have elected to continue to develop the NR2F6 program in-house prior to entering into any potential partnerships. The more mature the products, t...